Sharp Therapeutics (TSXV:SHRX) Operating Income: C$-7.67 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
14 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Operating Income?

Sharp Therapeutics TSXV:SHRX 14 Operating Income is C$-7.67 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 14/100.

Sharp Therapeutics's Operating Income for the three months ended in Dec. 2025 was C$-2.37 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was C$-7.67 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Sharp Therapeutics's Operating Income for the three months ended in Dec. 2025 was C$-2.37 Mil. Sharp Therapeutics's Revenue for the three months ended in Dec. 2025 was C$0.00 Mil. Therefore, Sharp Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 was %.

Sharp Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sharp Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 was -650.14%. Sharp Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,008.47%.

Sharp Therapeutics  (TSXV:SHRX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sharp Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-9.492 * ( 1 - 0% )/( (1.477 + 1.443)/ 2 )
=-9.492/1.46
=-650.14 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.192 - 0.447 - ( 2.757 - max(0, 0.596 - 2.864+2.757))
=1.477

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.693 - 1.167 - ( 1.32 - max(0, 1.317 - 1.4+1.32))
=1.443

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sharp Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.984/( ( (1.306 + max(-0.34, 0)) + (1.269 + max(-1.087, 0)) )/ 2 )
=-12.984/( ( 1.306 + 1.269 )/ 2 )
=-12.984/1.2875
=-1,008.47 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.107) - (0.447 + 0 + 0)
=-0.34

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.08) - (1.167 + 0 + 0)
=-1.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Sharp Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.373/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Sharp Therapeutics Operating Income Related Terms

Sharp Therapeutics Operating Income Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Operating Income Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Operating Income
-3.04 -6.49 -7.61

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Income Get a 7-Day Free Trial Premium Member Only -3.03 -1.90 -1.96 -1.44 -2.37
TSXV:SHRX
14GF Score
Sharp Therapeutics Corp TSXV:SHRX
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-7.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of C$-7.67 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Operating Income of C$-7.67 Mil as of Dec. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Operating Income too high?
Sharp Therapeutics' current Operating Income is C$-7.67 Mil. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Operating Income compare to VRTX and REGN?
Sharp Therapeutics' Operating Income of C$-7.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Operating Income is C$-7.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Operating Income of C$-7.67 Mil. The current Operating Income is C$-7.67 Mil. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Operating Income is C$-7.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score

Get the complete analysis for TSXV:SHRX

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price